count was 46 percent at week 4 (P<0.0001) and 100 percent at
week 16 (P=0.0002).
Similarly, there was a 45.5 percent median reduction in noninflammatory
lesion counts at week 4 (P<0.0001) and a 100
percent median reduction at week 16 (P=0.0002).
At baseline, 60 percent of subjects were rated as having
moderate PIH based on IGA, 20 percent had moderately severe